Opus Genetics Inc (IRD)

$2.36 -0.08 (-3.28%)
Market Cap 162.76M
Revenue (ttm) 10.99M
Net Income (ttm) -57.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -523.48%
Debt to Equity Ratio 0.18
Volume 334,500
Avg Vol 562,126
Day's Range N/A - N/A
Shares Out 68.96M
Stochastic %K 63%
Beta 0.42
Analysts Strong Sell
Price Target $7.78

Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal do...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
retro123
retro123 Dec. 12 at 3:21 PM
$IRD
0 · Reply
yft212
yft212 Dec. 11 at 11:50 PM
$IRD I'm curious as to why they would sell so much? https://ir.stockpr.com/opusgtx/sec-filings-email/content/0002042266-25-000003/primary_doc.html
1 · Reply
JoeD32
JoeD32 Dec. 11 at 3:52 PM
$IRD ahh the old tanking on all buys
0 · Reply
JohnTrack
JohnTrack Dec. 11 at 12:19 PM
$IRD news hint for the ticker... https://www.rapidticker.com/news/ird-opus-genetics-to-present-at-8752f4
0 · Reply
Um8a123
Um8a123 Dec. 11 at 12:17 AM
$IRD
0 · Reply
Atime2Buy
Atime2Buy Dec. 10 at 3:18 PM
$IRD strong buy
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 12:33 PM
B. Riley Securities updates rating for Opus Genetics ( $IRD ) to Buy, target set at 9.
0 · Reply
signaljumper
signaljumper Dec. 10 at 6:43 AM
$IRD Yesterday News https://ir.opusgtx.com/press-releases/detail/512/opus-genetics-announces-positive-recommendation-from-independent-data-monitoring-committee-for-phase-12-trial-in-best-disease
0 · Reply
signaljumper
signaljumper Dec. 10 at 6:30 AM
$IRD Yesterday we had a Higher Volume Trading day as the daily average volume
0 · Reply
Kathm65j
Kathm65j Dec. 10 at 1:12 AM
$IRD https://www.marketbeat.com/instant-alerts/equities-analysts-offer-predictions-for-opus-genetics-fy2025-earnings-2025-12-03/ ird going to roll
0 · Reply
Latest News on IRD
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 2 days ago

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Dec 9, 2025, 7:00 AM EST - 4 days ago

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 2, 2025, 4:01 PM EST - 11 days ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 20, 2025, 8:00 AM EST - 23 days ago

Opus Genetics to Participate in Upcoming Investment Conferences

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 13, 2025, 7:00 AM EST - 4 weeks ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 4 weeks ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 5 weeks ago

Opus Genetics Announces $23 Million Registered Direct Offering

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Nov 6, 2025, 7:00 AM EST - 5 weeks ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 14, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Oct 2, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics, Inc. - Special Call

Sep 30, 2025, 12:12 PM EDT - 2 months ago

Opus Genetics, Inc. - Special Call

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Sep 30, 2025, 7:00 AM EDT - 2 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 4, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Sep 2, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 27, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 18, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 4 months ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 5, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 23, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 4:30 PM EDT - 5 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 26, 2025, 6:55 AM EDT - 6 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Jun 23, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 11, 2025, 3:47 PM EDT - 8 months ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics to Participate in Upcoming Investor Conference in April

Apr 2, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Mar 31, 2025, 8:20 AM EDT - 9 months ago

Opus Genetics Announces Financial Results for Full Year 2024

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 5:03 PM EDT - 9 months ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:30 AM EDT - 9 months ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 21, 2025, 9:11 AM EDT - 9 months ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 5, 2025, 8:00 AM EST - 10 months ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 26, 2025, 8:00 AM EST - 10 months ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 18, 2025, 7:30 AM EST - 10 months ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Feb 7, 2025, 9:15 AM EST - 11 months ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Dec 19, 2024, 8:00 AM EST - 1 year ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

retro123
retro123 Dec. 12 at 3:21 PM
$IRD
0 · Reply
yft212
yft212 Dec. 11 at 11:50 PM
$IRD I'm curious as to why they would sell so much? https://ir.stockpr.com/opusgtx/sec-filings-email/content/0002042266-25-000003/primary_doc.html
1 · Reply
JoeD32
JoeD32 Dec. 11 at 3:52 PM
$IRD ahh the old tanking on all buys
0 · Reply
JohnTrack
JohnTrack Dec. 11 at 12:19 PM
$IRD news hint for the ticker... https://www.rapidticker.com/news/ird-opus-genetics-to-present-at-8752f4
0 · Reply
Um8a123
Um8a123 Dec. 11 at 12:17 AM
$IRD
0 · Reply
Atime2Buy
Atime2Buy Dec. 10 at 3:18 PM
$IRD strong buy
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 12:33 PM
B. Riley Securities updates rating for Opus Genetics ( $IRD ) to Buy, target set at 9.
0 · Reply
signaljumper
signaljumper Dec. 10 at 6:43 AM
$IRD Yesterday News https://ir.opusgtx.com/press-releases/detail/512/opus-genetics-announces-positive-recommendation-from-independent-data-monitoring-committee-for-phase-12-trial-in-best-disease
0 · Reply
signaljumper
signaljumper Dec. 10 at 6:30 AM
$IRD Yesterday we had a Higher Volume Trading day as the daily average volume
0 · Reply
Kathm65j
Kathm65j Dec. 10 at 1:12 AM
$IRD https://www.marketbeat.com/instant-alerts/equities-analysts-offer-predictions-for-opus-genetics-fy2025-earnings-2025-12-03/ ird going to roll
0 · Reply
JoeD32
JoeD32 Dec. 9 at 10:20 PM
$IRD huge sells after market 🤔
0 · Reply
merlynm
merlynm Dec. 9 at 9:26 PM
$IRD @ncost1 something for you?
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 9 at 6:07 PM
$IRD
0 · Reply
signaljumper
signaljumper Dec. 9 at 5:42 PM
$IRD strong move so far this remember we at the Last Run to 7 bucks a run over 200% This time the Pipeline is more developed than 1 year ago OS is still Low My target is 4.35 than 7 bucks
0 · Reply
annee33
annee33 Dec. 9 at 4:27 PM
$IRD breaking out, very quietly
0 · Reply
signaljumper
signaljumper Dec. 4 at 8:31 PM
$IRD 2.32 is the key to close above to See 3$+
0 · Reply
DGains
DGains Dec. 4 at 4:26 PM
$RYCEY Rolls-Royce Chillin’! 🏎️ $IRD Heating UP 🔥🛫 Volume Soon and $BYND Go Beyond! 💹 $META Beast Mode! 🦍
0 · Reply
Um8a123
Um8a123 Dec. 3 at 5:39 PM
$IRD
0 · Reply
alexquick123
alexquick123 Dec. 3 at 2:02 PM
$IRD just drop like you always do, your not him, let’s be honest. I need to reload my shares.
0 · Reply
signaljumper
signaljumper Nov. 28 at 4:58 PM
$IRD 2.32 IS the key to Close above in the next days to See 3 bucks
0 · Reply
TheAliAbdul
TheAliAbdul Nov. 28 at 3:52 PM
$IRD Next resistance at $2.15 and then all the way to $2.37?
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 2:22 PM
Piper Sandler has updated their rating for Opus Genetics ( $IRD ) to Overweight with a price target of 7.
0 · Reply